Biopsy Devices – Market Insights – Europe

The European biopsy device market was negatively impacted by the COVID-19 pandemic. However, overall biopsy procedure volumes will continue to grow marginally through 2032, driven by rise in cancer screenings as well as updated recommendations to screening guidelines. In addition, the ongoing shift from reusable to disposable devices, coupled with improved patient perceptions surrounding biopsy procedures and screening tests, will have a significant positive impact on the market; overall, these factors will support continued market growth during the forecast period.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for biopsy devices in Europe from 2019 through 2032.

COVID-19 pandemic has negatively impacted the European biopsy devices market, affecting procedure volumes and device segments.

To what extent has the COVID-19 pandemic impacted the biopsy device market in Europe?

Which procedures were affected the most during the pandemic?

How quickly procedure volumes recovered?

Implementation of new cancer screening programs will support the growth of European biopsy device market.

What cancer screening programs were recently launched, and how will they impact the market?

How are CRC screening programs affecting market dynamics in Europe?

How are breast cancer screening programs affecting market dynamics in Europe?

Minimally invasive, alternative technologies to tissue biopsy are being adopted by physicians in the Europe.

To what extent are physicians adopting these minimally invasive technologies?

How will the adoption of alternative technologies impact the biopsy device market?

Which major players are impacting the biopsy device market and how? 

Who all are the major competitors in each market segment?

Which companies have been involved in recent market developments? How does this affect the market?

Table of contents